secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001104659-23-053509
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics sells manufacturing assets for $19M, appoints Juan Vera as CEO, extends runway to end of 2025
--------------------------------------------------------------------------------

- CellReady to purchase Marker's manufacturing assets for ~$19M in cash; annual overhead reduced by ~$11M; closing targeted June 26, 2023.
- CEO Peter Hoang resigns effective May 1; board appoints Juan Vera (formerly COO/CSO) as President and CEO.
- Non-dilutive deal extends Marker's financial runway through year-end 2025; net benefit estimated at ~$42M.
- Clinical priorities: MT-601 in NHL trial, MT-401 in post-transplant AML; data expected H2 2024.
- Board member David Laskow-Pooley will not stand for reelection at 2023 annual meeting, term expires then.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/0001104659-23-053509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/tm2314110d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-053509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer